Valuation Stories

APYX
  over two months ago at Macroaxis 
By Raphi Shpitalnik
As many millenniums are excited about healthcare space, it is only fair to break down Apyx Medical Corp. We will check why this entity may not get much respect from investors given the current market uncertainty. Is Apyx Medical Corp current valuation justified for 2022? Here i will cover my perspective on valuation to give Apyx Medical investors a better outlook on taking a position in the stock.
IDYA
  over two months ago at Macroaxis 
By Vlad Skutelnik
As many millenniums are excited about healthcare space, it is only fair to go over Ideaya Biosciences. We will try to explain if it is still possible for Ideaya Biosciences to generate above-average margins. Is the entity current valuation justified for 2022? Here i will cover my perspective on valuation to give Ideaya investors a better outlook on taking a position in the stock.
ASLE
  over two months ago at Macroaxis 
By Ellen Johnson
As many millenniums are excited about industrials space, it is only fair to digest Aersale Corp. We will evaluate why we are still confident in anticipation of a recovery. Is current Aersale Corp value sustainable? We will go over the firm valuation drivers to give you a better outlook on taking a position in it.
DMAC
  over two months ago at Macroaxis 
By Vlad Skutelnik
While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to go over Diamedica Therapeutics. We will analyze why it could be a much better year for Diamedica Therapeutics shareholders. Is the firm valuation sustainable? Here I will cover a perspective on valuation of Diamedica to give you a better outlook on taking a position in this stock.
MTBC
  over two months ago at Macroaxis 
By Vlad Skutelnik
As many investors are getting excited about healthcare space, it is fair to go over Carecloud. We will evaluate if Carecloud shares are reasonably priced going into April. Is the firm current valuation justified? We will cover Carecloud valuation to give you a better outlook on taking a position in the stock.
BTTR
  over two months ago at Macroaxis 
By Gabriel Shpitalnik
While some baby boomers are getting worried about consumer defensive space, it is reasonable to sum up Better Choice. We will evaluate why recent Better Choice price moves suggest a bounce in April. Is the firm current valuation justified for 2022? Here i will cover my perspective on valuation to give Better retail investors a better outlook on taking a position in the stock.
AMPH
  over two months ago at Macroaxis 
By Raphi Shpitalnik
While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to concentrate on Amphastar Pharma. What exactly are Amphastar Pharma shareholders getting in April? Is Amphastar Pharma valuation sustainable? Here I will cover a perspective on valuation of Amphastar to give you a better outlook on taking a position in this stock.
BXRX
  over two months ago at Macroaxis 
By Raphi Shpitalnik
As many investors are getting excited about healthcare space, it is fair to break down Baudax Bio. We will evaluate why recent Baudax Bio price moves suggest a bounce in April. What is Baudax Bio valuation so far in 2022? We are going to cover the firm perspective on valuation to give investors a better transparency on taking a position in it.
BKE
  over two months ago at Macroaxis 
By Ellen Johnson
As many of us are excited about consumer cyclical space, it is fair to digest Buckle Inc. We will evaluate why we are still confident in anticipation of a recovery. Is Buckle Inc valuation justified? Here we go over the entity perspective on valuation to give you a better outlook on taking a position in this stock.
GASS
  over two months ago at Macroaxis 
By Raphi Shpitalnik
As many of us are excited about industrials space, it is fair to sum up Stealthgas. We will evaluate why we are still confident in anticipation of a recovery. Is the firm valuation justified? Here I will cover 2022 perspective on the current valuation of Stealthgas to give you a better outlook on taking a possible position in this stock.